Announced
Completed
Financials
Sources
Tags
Friendly
Cross Border
Venture Capital
Biotechnology
Acquisition
Completed
biopharma
Minority
Private Equity
Single Bidder
China
Private
Synopsis
Oceanpine and OrbiMed co-led the $130m Series B funding round for Yisheng Biopharma, a global biopharmaceutical company, headquartered in Beijing. Institutional investors also include: EightRoad, F-Prime Capital, 3W Capital, Hillhouse Capital, Adjuvant Capital, MSA Capital, AIHC, Epiphron Capital, Superstring Capital, Haitong International. This round of funding will strongly support the expansion of the company's R&D center, accelerate our commercialization strategies including the clinical development of multiple vaccine candidates and the construction of biologics production facilities in China and Singapore.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.